Population pharmacokinetic and exposure‐response analyses from ALTA‐1L: Model‐based analyses supporting the brigatinib dose in ALK‐positive NSCLC

• Main Authors: Neeraj Gupta (Author), Karen L. Reckamp (Author), David R. Camidge (Author), Huub J. Kleijn (Author), Aziz Ouerdani (Author), Francesco Bellanti (Author), John Maringwa (Author), Michael J. Hanley (Author), Shining Wang (Author), Pingkuan Zhang (Author), Karthik Venkatakrishnan (Author)
• Format: Book
• Published: Wiley, 2022-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract The ALK in Lung Cancer Trial of brigAtinib in First Line (ALTA‐1L) compared brigatinib versus crizotinib in anaplastic lymphoma kinase (ALK) inhibitor‐naive patients with ALK+ non‐small cell lung cancer (NSCLC). A population pharmacokinetic (PK) model was used to estimate brigatinib exposur...